Showing posts with label Future. Show all posts
Showing posts with label Future. Show all posts

Tuesday, December 6, 2011

Learning the History of Prostate Cancer to Know Its Future

Prostate cancer was first described by anatomist Niccolo Massa in 1536 but was not officially identified until 1853. A the time, prostate cancer was considered a rare disease, due to the shorter life expectancies of the population and poor detection methods.

The first surgical treatment happened in the 1890s and was limited in its success. Removal of the actual prostate gland was first performed in 1904.

Alternative Cancer Treatments

Treatments such as retropubic prostatectomy was developed in 1983 by Patrick Walsh. This surgical approach allowed for removal of the prostate and lymph nodes with maintenance of penile function.

In 1941 Charles Higgens published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical castration" won Huggins the 1966 Nobel Prize in Medicine.

Treatments such as retropubic prostatectomy was developed in 1983 by Patrick Walsh. This surgical approach allowed for removal of the prostate and lymph nodes with maintenance of penile function.

Radiation therapy for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic radium implants. External beam radiation became more popular as stronger radiation sources became available in the middle of the 20th century. Systemic chemotherapy for prostate cancer was first studied in the 1970s. Brachytherapy with implanted seeds was first described in 1983.

Research into different treatments and complementary treatments is ongoing and important even though as a type of cancer, prostate cancer is one of the easiest to treat, provided it is detected in its early stages. Screening procedures are also under research as there is no one main cause that has been found for prostate cancer.

Learning the History of Prostate Cancer to Know Its Future

Alternative Cancer Treatments

Saturday, October 22, 2011

The Future of Colon Cancer Treatment

Future study of colorectal cancer will refine our understanding of the genetics of the disease. This in turn will lead to earlier identification and treatment of high-risk persons. The future may possibly bring the use of genetic interventions to interrupt the adenoma-carcinoma sequence.

Increased awareness of colorectal cancer by the public and by private insurers, government agencies, and medical personnel will result in better use of available screening techniques. Development of preventive drug strategies against colorectal cancer, particularly with drugs that reduce polyp formation or prevent polyp progression to cancer, promises to be a fruitful field of endeavor.

Cancer Treatments

There is ample reason to expect refinement of diagnostic and staging tests for the disease, perfection of surgical and nonsurgical techniques for treatment of large bowel cancer and its complications, and improving chemotherapeutic treatment by means of more effective and less toxic drugs.

A number of molecular markers for colorectal cancer can be measured but it is not yet clear that they have prognostic value or therapeutic implications. Measures of DNA synthesis or cell division are of uncertain value as clinical decision-making tools. Measurement of thymidilate synthase activity in colorectal cancer tissue is one of several markers under investigation as a prognostic indicator.

This could be useful in making decisions regarding the use of adjuvant chemotherapy for certain patients, especially those with stage II or B tumors. Another goal would be to collect a set of markers for cancer risk for an individual who has adenomatous polyps. Presumably, such testing could reflect exposure to colon carcinogens and help define the outlook for an individual. This in turn could narrow the prospective use of screening and diagnostic procedures such as colonoscopy.

Techniques to identify micrometastases in lymph node tissue are in development. These include special stains for cytokeratin, which can identify small clusters or single malignant cells in lymph node tissue. Another method uses a technique known as PCR for detection of CEA in resected lymph nodes. PCR is a technique which permits rapid reproduction of large quantities of short segments of DNA or RNA.

Other techniques include the identification in lymph node tissue of oncogene, or tumor suppressor gene mutations, which occur in the primary tumor. Such techniques may be of use in reclassifying patients whose lesions are stages as II or B by conventional means and in selecting them for potentially life-saving adjuvant chemotherapy. Large clinical trials will be needed to determine if identification of micrometastases by these methods indeed leads to more appropriate treatment and improved progress.

Expression of the enzyme COX-2 by colorectal cancers is highly variable. Greater expressions of COX-2 by tumors are associated with lymph node metastasis, advanced stage of cancer, and poorer long-term outlook for patients. Thus, there could be potential future application of this test as a means of staging and prognostication.

The Future of Colon Cancer Treatment

Cancer Treatments

Thursday, October 20, 2011

Prostate Cancer Patients Have A Brighter Future With Ketoconazole

No doubt, you are confused and feel helpless when you are diagnosed with cancer of the prostate gland, but today there's hope for millions suffering from this type of cancer in the form of the wonder drug Ketoconazole. Earlier the fear of surgery and castration had huge psychological effects but now it has been found that therapy depriving the patient of androgen can be administered in a much more humane way. Ketoconazole can work magic by way of combating prostate cancer.

To lower androgen levels, what medical specialists now prescribe is the application of HDK or High-Dose Ketoconazole. The substance acts as a barrier and controls secretions from the endocrine glands. In this way, the production of testosterone is diminished and logically it works like Androgen Deprivation Therapy or ADT, as it is commonly called. The previous custom of performing surgery on the genital area to deprive the prostate of the hormone androgen can thus be avoided.

Cancer Treatments

Ketoconazole hinders the enzyme P450. Laboratory experiments have proven the ability of Ketoconazole to kill cancer cells. However, a more complete treatment is to administer doses of the combination of Ketoconazole and Hydrocortisone. They complement each other. While the Ketoconazole hinders the secretion of testosterone, the synthetic Hydrocortisone is a substitute for the cortisol in the body.

If the body rejects High-Dose Ketoconazole, LDK or Low-Dose Ketoconazole may be administered instead. This, as the name suggests, is a lower dose of Ketoconazole. It has been found that the results are as good as those after treatment with HDK.

Medical specialists advise HDK to be taken three times a day in the first week. The recommended strength is 200 mg. The dosage of HDK is then raised to double the strength. However, the timings don't alter. To be efficacious, Ketoconazole is best taken on an empty stomach. The ideal time is midway between meals. That would be approximately two hours after one meal and two hours before the next. The reason is that absorption of Ketoconazole is much faster on an empty stomach, without the interference from other substances in medications such as histamines.

Hydrocortisone on the other hand is best taken with food. Take great precautions as to the dosage. Stick to what the doctor has prescribed. An overdose of Hydrocortisone could result in edema, especially around the ankles. If such a manifestation should occur, don't under any circumstances stop taking the drug abruptly. The dosage should be gradually tapered off.

Ketoconazole is the answer to the prayers of millions of people suffering from prostate cancer. It has the potential to give the sufferer another chance at life, as it curbs the malignant cells through efficiently preventing enzymes from degenerating. Medications that have the generic name Ketoconazole is what you should talk to your doctor about.

Prostate Cancer Patients Have A Brighter Future With Ketoconazole

Cancer Treatments

Monday, October 3, 2011

Future Treatments for Breast Cancer

Standard treatment for breast cancer has greatly improved survival for women, but the fact remains that 40% of women still ultimately die from the disease. This fact highlights theneed for new and better therapies. Traditional anticancer therapies mostly consist of drugs and ionizing radiation that damage DNA and DNA machinery. Such treatments preferentially kill certain kinds of cancer cells because these cells have a diminished ability to survive the damage. However, normal cells, can suffer DNA damage, but have the ability to repair their DNA. Unfortunately, the same genetic defects may render some cancer cells resistant to treatment, since they may also be less adept at activating cell death in the face of DNA damage. The challenge of cancer treatment now is to take advantage of properties of cancer cells that distinguish them from normal cells and to subsequently and specifically target cancer cells. A growing understanding of cancer cell biology is leading to better methods for treating the disease by directly exterminating only cancer cells. Listed are some of the latest new and adventurous strategies that are being developed for future breast cancer diagnosis and treatment.

Six new breast cancer treatment strategies

Cancer Treatments

1. Oncolytic viral therapy - takes advantage of molecules that tumor cells lack. Tumor cells usually lack the protein p53 which controls the cell cycle and cell replication. Viruses can attach to a host cell and replicate continuously inside the cell. They then burst out when their numbers are sufficient, killing the cell and infecting its neighbors. An adenovirus has now been constructed that lacks the gene for the p53 protein; this virus can therefore only replicate in cells in which p53 is already inactivated-including many types of cancer cells. If this modified adenovirus is injected into a tumor, it will replicate in and kill only the cancer cells that lack p53, leaving normal cells unharmed. This strategy is presently undergoing clinical trials.

2. Interventional Radiology - Scientists are investigating a technique in which magnets are used to pull chemotherapy drugs into tumors. Microscopic magnetic particles are attached to the cancer drugs and infused into the blood vessel that feeds the tumor. A rare earth magnet is positioned directly above the tumor site. The magnet pulls the drug-carrying particles out of the blood vessel directly into the tumor. This technique is still experimental; however, early research is promising. Scientists hope that it will bolster the effects of chemotherapy and avoid drug side effects.

3. Gene Therapy - involves the alteration of the patient's genetic material to fight or prevent cancer. Although the science of gene therapy is still in the experimental stages, researchers hope that in the future the therapy can be used as follows:

Alter the cells of a patient's natural immune system with cancer-fighting genes that allow cells to more forcefully attack the cancer; Genetically alter cancer cells so that the patient's own immune system will defend against them and allow the altered cancer cells to act as a cancer vaccine; Replace genes responsible for cancer growth with "good" genes; and inject a tumor with genes that will make it more susceptible to cancer-fighting agents. Make normal tissue resistant to chemotherapy, so that drugs will destroy tumors without damaging healthy tissue.

4. Breast Cancer vaccines - Vaccination strategies are being developed that engage the patient's own immune system to eradicate cancer cells. The advantage of this is low toxicity, and high specificity as well as a sustained antibody effect due to cell memory.

5. Use of breast cancer resistance genes - Researchers at the Dana Faber Cancer Institute have found a gene that can predict a high risk of cancer recurrence in some breast cancers that have been treated with chemotherapy drugs. This finding could guide the physician in the choice of anti-tumor drugs to use and eliminate wrong ineffective choices.

6. More precise breast cancer diagnosis - Breast cancer can now be characterized at a molecular level by obtaining expression profiles for thousands of genes within the cancer. These profiles can be grouped into subclasses of breast cancers that share common features such as prognosis and probable response to certain treatments. More precise treatments can then be made for each subclass of cancer

To find out about the author and her primary business, visit the author's

Future Treatments for Breast Cancer

Cancer Treatments